Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835
Books209
All textbooksMedical textbooksHuman anatomyOrganisms & biodiversityOther sciences
Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›Take-home naloxone in multicentre emergency settings: the TIME feasibility cluster RCT›References

Continue where you left off ()

GO BEYOND THE PAGEReading is just the beginning.

Turn scientific reading into research. Compare studies, examine evidence, and organize your findings in EvidenceHelix Workspace.

Explore Research Workspace →

Take-home naloxone in multicentre emergency settings: the TIME feasibility cluster RCT · References

References

CC BY 4.0 · National Institute for Health and Care Research · approximately 9 min read

  1. Jones M, Bell F, Benger J, Black S, Buykx P, Dixon S, et al. Protocol for Take-home naloxone In Multicentre Emergency (TIME) settings: feasibility study. Pilot Feasib Stud 2020;6(1):1–10.
  2. Lewer D, Brothers TD, Van Hest N, Hickman M, Holland A, Padmanathan P, Zaninotto P. Causes of death among people who used illicit opioids in England, 2001–18: a matched cohort study. Lancet Publ Health 2022;7(2):e126–35.
  3. Snowdon J. Drug overdose death rates in different countries: who should be alarmed? Austral Psychiat 2022;30(1):26–30.
  4. van Amsterdam J, van den Brink W, Pierce M. Explaining the differences in opioid overdose deaths between Scotland and England/Wales: implications for European opioid policies. Eur Addict Res 2021;27(6):399–412.33965949
  5. Pierce M, van Amsterdam J, Kalkman GA, Schellekens A, van den Brink W. Is Europe facing an opioid crisis like the United States? An analysis of opioid use and related adverse effects in 19 European countries between 2010 and 2018. Eur Psychiat 2021;64(1):e47.
  6. Black C. Review of Drugs: Phase One Report. London: Gov. UK; 2020.
  7. Shearing H. Drug deaths in England and Wales highest since 1993. BBC 2021.
  8. Ely J. Britain’s cocaine epidemic laid bare: Drug deaths hit record high with coke fatalities up 7-FOLD in decade as experts blame COVID lockdowns for fuelling addiction crisis and middle class’s love for ‘gear’ (which is delivered quicker than pizza!). Daily Mail 2022.
  9. McKenzie S. CNN. 2021. URL: https://edition.cnn.com/2021/08/07/europe/trainspotting-scotland-drug-related-deaths-cmd-intl/index.html (accessed 28 September 2023).
  10. Lewer D, Padmanathan P, Qummerul Arfeen Q, Denaxas S, Forbes H, Gonzalez-Izquierdo A, et al. Healthcare use by people who use illicit opioids (HUPIO): development of a cohort based on electronic primary care records in England. Wellcome Open Res 2020;5:282.33659712
  11. O’Mara B. The effectiveness of changes to drug policy, regulation and legislation for reducing harms associated with opioids and supporting their medicinal use in Australia, Canada and the UK: a systematic review. Evid Base: J Evid Rev Key Policy Areas 2020;2020:79–110.
  12. Alho H, Dematteis M, Lembo D, Maremmani I, Roncero C, Somaini L. Opioid-related deaths in Europe: strategies for a comprehensive approach to address a major public health concern. Int J Drug Policy 2020;76:102616.31855706
  13. Zibbell J, Howard J, Clarke SD, Ferrell A, Karon S. Non-Fatal Opioid Overdose and Associated Health Outcomes: Final Summary Report. US Department of Health and Human Services; 2019.
  14. Jiang R, Lee I, Lee TA, Pickard AS. The societal cost of heroin use disorder in the United States. PLOS ONE 2017;12(5):e0177323.28557994
  15. Warner‐Smith M, Darke S, Day C. Morbidity associated with non‐fatal heroin overdose. Addiction 2002;97(8):963–7.12144598
  16. Stoové MA, Dietze PM, Jolley D. Overdose deaths following previous non‐fatal heroin overdose: record linkage of ambulance attendance and death registry data. Drug Alcohol Rev 2009;28(4):347–52.19594787
  17. Ryan JM, Spronken I. Drug related deaths in the community: a preventive role for accident and emergency departments? J Accid Emer Med 2000;17(4):272–3.
  18. Baca CT, Grant KJ. Take‐home naloxone to reduce heroin death. Addiction 2005;100(12):1823–31.16367983
  19. Public Health England. Take-Home Naloxone for Opioid Overdose in People Who Use Drugs. London: Public Health England; 2017.
  20. Yealy DM, Paris PM, Kaplan RM, Heller MB, Marini SE. The safety of prehospital naloxone administration by paramedics. Ann Emerg Med 1990;19(8):902–5.2372173
  21. McDonald R, Strang J. Are take‐home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction 2016;111(7):1177–87.27028542
  22. Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ 2013;346:f174.23372174
  23. Kerensky T, Walley AY. Opioid overdose prevention and naloxone rescue kits: what we know and what we don’t know. Addict Sci Clin Pract 2017;12(1):4.28061909
  24. World Health Organization. WHO-UNODC ‘Stop Overdose Safely (SOS)’ Initiative. Geneva: World Health Organization; 2020.
  25. Advisory Council on the Misuse of Drugs. Consideration of Naloxone. 2012.
  26. European Monitoring Centre for Drug and Drug Addiction. Take-Home Naloxone. European Monitoring Centre for Drug and Drug Addiction website: European Monitoring Centre for Drug and Drug Addiction; 2020.
  27. McDonald R, Campbell ND, Strang J. Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids: conception and maturation. Drug Alcohol Depend 2017;178:176–87.28654870
  28. Public Health Wales. Substance Misuse: Harm Reduction Database Wales (HRD). Contract no.: 29/06/2022, Online. Wales: Public Health Wales; 2018.
  29. Skulberg AK, Tylleskär I, Valberg M, Braarud A-C, Dale J, Heyerdahl F, et al. Comparison of intranasal and intramuscular naloxone in opioid overdoses managed by ambulance staff: a double-dummy, randomised, controlled trial. Addiction 2022;117(6):1658–67.35137493
  30. Rege SV, Ngo DA, Ait-Daoud N, Sharma S, Verplancken E, Holstege CP. Trends and characteristics of naloxone therapy reported to US poison centers. Addiction 2018;113(12):2309–15.29989286
  31. Rzasa Lynn R, Galinkin J. Naloxone dosage for opioid reversal: current evidence and clinical implications. Therap Adv Drug Safe 2018;9(1):63–88.
  32. Moustaqim-Barrette A, Dhillon D, Ng J, Sundvick K, Ali F, Elton-Marshall T, et al. Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review. BMC Publ Health 2021;21(1):597.
  33. Public Health Wales. Harm Reduction Database Wales: Take-Home Naloxone. Contract No.: 29/06/2022, Online. Wales: Public Health Wales; 2016.
  34. Public Health Scotland. National Naloxone Programme Scotland: Annual Monitoring Report 2019/20 and 2020/21. Glasgow: Public Health Scotland; 2022.
  35. Stam NC, Gerostamoulos D, Smith K, Pilgrim JL, Drummer OH. Challenges with take-home naloxone in reducing heroin mortality: a review of fatal heroin overdose cases in Victoria, Australia. Clin Toxicol 2019;57(5):325–30.
  36. Moore C, Lloyd G, Oretti R, Russell I, Snooks H. Paramedic-supplied ‘Take Home’ Naloxone: protocol for cluster randomised feasibility study. BMJ Open 2014;4(3):e004712.
  37. Dwyer K, Walley AY, Langlois BK, Mitchell PM, Nelson KP, Cromwell J, Bernstein E. Opioid education and nasal naloxone rescue kits in the emergency department. Western J Emerg Med 2015;16(3):381–4.
  38. Gunn AH, Smothers ZP, Schramm-Sapyta N, Freiermuth CE, MacEachern M, Muzyk AJ. The emergency department as an opportunity for naloxone distribution. Western J Emerg Med 2018;19(6):1036–42.
  39. European Monitoring Centre for Drug and Drug Addiction. United Kingdom Country Drug Report. 2019.
  40. Welsh Government. Working Together To Reduce Harm: Substance Misuse Annual Report and Forward Look 2018. Welsh: Welsh Government; 2018.
  41. Turner D, Morgan G, Smith J. Harm Reduction Database Wales; Take Home Naloxone. Wales: Public Health Wales; 2018.
  42. NHS Scotland. National Naloxone Programme Scotland Monitoring Report 2017/2018. Information Services Division Scotland: NHS National Services Scotland; 2018.
  43. NHS Scotland. Prevalence of Problem Drug Use in Scotland 2015/16 Estimates. NHS National Services Scotland: Information Services Division Scotland; 2019.
  44. McDonald R, Eide D, Abel-Ollo K, Barnsdale L, Carter B, Clausen T, et al. A rapid assessment of take-home naloxone provision during COVID-19 in Europe. Int J Drug Policy 2022;107:103787.35849935
  45. Tas B, Humphreys K, McDonald RS, Strang JS. Should we worry that take-home naloxone availability may increase opioid use? Addiction 2019; 114(10):1723–5.31013396
  46. Abdelal R, Banerjee AR, Carlberg-Racich S, Darwaza N, Ito D, Epstein J. The need for multiple naloxone administrations for opioid overdose reversals: a review of the literature. Subst Abus 2022;43(1):774–84.35112993
  47. Tse WC, Djordjevic F, Borja V, Picco L, Lam T, Olsen A, et al. Does naloxone provision lead to increased substance use? A systematic review to assess if there is evidence of a ‘moral hazard’ associated with naloxone supply. Int J Drug Policy 2022;100:103513.34798434
  48. McAuley A, Bouttell J, Barnsdale L, Mackay D, Lewsey J, Hunter C, Robinson M. Evaluating the impact of a national naloxone programme on ambulance attendance at overdose incidents: a controlled time–series analysis. Addiction 2017;112(2):301–8.27614084
  49. Moore C, Lloyd G, Oretti R, Russell IT, Snooks H. Paramedic Supplied ‘Take Home’ Naloxone: A Randomised Feasibility Study. BMJ Publishing Group Ltd and the British Association for Accident; 2016.
  50. Kestler A, Buxton J, Meckling G, Giesler A, Lee M, Fuller K, et al. Factors associated with participation in an emergency department–based take-home naloxone program for at-risk opioid users. Ann Emerg Med 2017;69(3):340–6.27745764
  51. Public Health England. Adult Substance Misuse Treatment Statistics 2019–2020: Report. London: Public Health England; 2020.
  52. Bradbury M, Lewer D. Role of community drug and alcohol services in physical healthcare for people who use illicit opioids: a qualitative study of clinical staff in the UK. BMJ Open 2021;11(7):e046577.
  53. Lyons RA, Jones KH, John G, Brooks CJ, Verplancke J-P, Ford DV, et al. The SAIL databank: linking multiple health and social care datasets. BMC Med Inform Decis Mak 2009;9:1–8.19138407
  54. Digital Health and Care Wales. PEDW Data Online. URL: https://dhcw.nhs.wales/information-services/health-intelligence/pedw-data-online/ (accessed 28 September 2023).
  55. Fuller GW, Jones M, Bradshaw CA, Jones J, John A, Snooks H, Watkins A. The socio-demographics and health service use of opioid overdose decedents in Wales: a cross-sectional data linkage study. Eur Addict Res 2022;28(3):226–30.35172309
  56. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ 2014;348:g1687.24609605
  57. Dowling J, Isbister GK, Kirkpatrick CM, Naidoo D, Graudins A. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit 2008;30(4):490–6.18641540
  58. Kerr D, Kelly AM, Dietze P, Jolley D, Barger B. Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction 2009;104(12):2067–74.19922572
  59. Kelly AM, Kerr D, Koutsogiannis Z, Dietze P, Patrick I, Walker T. Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose. Med J Aust 2005;182(1):24–7.15651944
  60. Furyk JS, Lawton LD, Ting JY, McD Taylor D; Group ACfEMCT. Informed consent in emergency care research: an oxymoron? Emerg Med Austral 2017;29(1):110–2.
  61. May C, Finch T. Implementing, embedding, and integrating practices: an outline of normalization process theory. Sociology 2009;43(3):535–54.
  62. Jones KC, Burns A. Unit Costs of Health and Social Care 2021. URL: https://kar.kent.ac.uk/92342 (accessed 25 June 2024).
  63. NHS England. NHS England National Cost Collection 2020/21 Index. 2022.
  64. Murray E, Treweek S, Pope C, MacFarlane A, Ballini L, Dowrick C, et al. Normalisation process theory: a framework for developing, evaluating and implementing complex interventions. BMC Med 2010;8(1):1–11.20051100
  65. Corbin J, Strauss A. Basics of Qualitative Research. Thousand Oaks, CA: SAGE Publications Ltd; 2015.
  66. Silverman D. Doing Qualitative Research: A Practical Handbook. Thousand Oaks, CA: SAGE Publications Ltd; 2013.
  67. Berends L, Johnston J. Using multiple coders to enhance qualitative analysis: The case of interviews with consumers of drug treatment. Addict Res Theor 2005;13(4):373–81.
  68. Huddlestone L, Turner J, Eborall H, Hudson N, Davies M, Martin G. Application of normalisation process theory in understanding implementation processes in primary care settings in the UK: a systematic review. BMC Fam Pract 2020;21(1):1–16.31901226
  69. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; PAFS Consensus Group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ 2016;355:i5239.27777223
  70. Wait S. Engaging nurses in patient recruitment to research trials in the emergency department. Emerg Nurse 2022;31(5):27–31.
  71. Langham S, Wright A, Kenworthy J, Grieve R, Dunlop WC. Cost-effectiveness of take-home naloxone for the prevention of overdose fatalities among heroin users in the United Kingdom. Value Health 2018;21(4):407–15.29680097
  72. UK Standards for Public Involvement. URL: https://sites.google.com/nihr.ac.uk/pi-standards/standards (accessed 15 January 2024).
  73. Evans BA, Porter A, Snooks H, Burholt V. A co-produced method to involve service users in research: the SUCCESS model. BMC Med Res Methodol 2019;19(1):1–10.30611213
  74. Jinks C, Carter P, Rhodes C, Taylor R, Beech R, Dziedzic K, et al. Patient and public involvement in primary care research: an example of ensuring its sustainability. Res Invol Engag 2016;2(1):1.
  75. Evans BA, Carson-Stevens A, Cooper A, Davies F, Edwards M, Harrington B, et al. Implementing public involvement throughout the research process: experience and learning from the GPs in EDs study. Health Expect 2022;25:2471–84.35894169
  76. Staley K. Changing what researchers’ think and do’: is this how involvement impacts on research? Research for All 2017;1:158–67.
  77. Staniszewska S, Brett J, Mockford C, Barber R. The GRIPP checklist: strengthening the quality of patient and public involvement reporting in research. Int J Technol Assess Health Care 2011;27(4):391–9.22004782
  78. Scharf BM, Sabat DJ, Brothers JM, Margolis AM, Levy MJ. Best practices for a novel EMS: based naloxone leave behind program. Prehosp Emerg Care 2021;25(3):418–26.32420791
  79. Drainoni M-L, Koppelman EA, Feldman JA, Walley AY, Mitchell PM, Ellison J, Bernstein E. Why is it so hard to implement change? A qualitative examination of barriers and facilitators to distribution of naloxone for overdose prevention in a safety net environment. BMC Res Notes 2016;9(1):465.27756427
  80. Lacroix L, Thurgur L, Orkin AM, Perry JJ, Stiell IG. Emergency physicians’ attitudes and perceived barriers to the implementation of take-home naloxone programs in Canadian emergency departments. CJEM 2018;20(1):46–52.28918769
  81. Funke M, Kaplan MC, Glover H, Schramm-Sapyta N, Muzyk A, Mando-Vandrick J, et al. Increasing naloxone prescribing in the emergency department through education and electronic medical record work-aids. Joint Commiss J Qual Patient Safe 2021;47(6):364–75.
← Discussion, conclusion and recommendationsAdditional information →

Attribution. Helen Snooks; Jonathan Benger; Fiona Bell; Sarah Black; Simon Dixon; Helena Emery et al. (2024). Take-home naloxone in multicentre emergency settings: the TIME feasibility cluster RCT. National Institute for Health and Care Research. Copyright © 2024 Snooks et al. Licensed under CC BY 4.0. NCBI Bookshelf NBK608691. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • References

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support